How one virus uses mimicry to replicate successfully

October 31, 2007

(PHILADELPHIA) - Both viruses and cancers subvert the growth-control machinery in a cell to serve their own needs. According to a new study, at least one virus uses mimicry to gain access to that machinery.

A common target for both is a cell protein called the retinoblastoma protein, or pRb, which serves to block cell division when potentially cancer-causing gene mutations are present. First identified in pediatric tumors of the retina, this tumor suppressor protein has since been found to play a role in many other forms of cancer when disrupted.

A number of viruses produce proteins that specifically target pRb, and scientists have studied these viruses and their proteins closely to better understand how normal cells can turn cancerous. Among such viruses are the adenoviruses, which produce a protein called E1A that interferes with pRb and its ability to control unwanted cell division. Adenoviruses are not themselves cancer causing, but a better understanding of how they interact with pRb might well shed light on related mechanisms used by other viruses to trigger cancers. For example, a protein that is functionally equivalent to E1A from human papillomavirus, called E7, causes cervical cancer in the cells it infects.

Until now, investigators had been unable to obtain detailed information about how E1A disrupts the normal function of pRb. In a new study, however, featured on the cover of the November 1 issue of the journal Genes & Development, researchers at The Wistar Institute have solved the three-dimensional structure of a molecular complex of pRb and E1A, providing the first atomic view of the viral E1A protein in action.

The findings show that that E1A operates in a novel way, mimicking a normal cellular protein called E2F that ordinarily binds to pRb in a controlled and regulated fashion.

"The structural similarities between E1A and E2F are surprising and striking," says Ronen Marmorstein, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author on the study. "Looking at the structure it became obvious how this viral protein disrupts the activity of pRb."

pRb is a member of the "pocket-protein family," because it has a pocket within which proteins can bind. For pRb to function normally, it needs to bind a molecular complex incorporating the E2F protein. When pRb is bound to this complex, it acts as a growth suppressor, inhibiting cell division.

In their study, Marmorstein and a colleague showed that E1A disables pRb and its ability to control cell division by mimicking E2F and occupying the same pocket where E2F would normally bind.

"Looking at the structure, we see that the E1A protein displaces E2F by binding to a specific location on pRb," Marmorstein says. "By knocking out pRb in this manner, E1A forces cells to start dividing uncontrollably, a hallmark of cancer."

This approach to targeting pRb is quite different from methods used by other viral proteins, he adds.

The study provides the first structural information on the E1A protein. In developing the required crystals for the structure determination, Xin Liu, the lead author on the study, first had to identify suitable binding partners for the protein.

"Because E1A is so flexible, it needs binding partners to crystallize," Liu says.

By forming a complex with pRb and these binding partners, the researchers were able to crystallize the protein and then analyze its structure using a technique called X-ray crystallography. Their studies revealed how each component of the complex worked in three-dimensional detail.

The scientists are now working to analyze the structure of larger regions of the E1A protein bound to pRb and other cellular E1A targets to more fully characterize how this viral mechanism might cause cancer.
-end-
The research was supported by grants from the National Institutes of Health and the Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has long held the prestigious Cancer Center designation from the National Cancer Institute. Discoveries at Wistar led to the creation of the rubella vaccine that eradicated the disease in the United States, human rabies vaccines used worldwide, and a new rotavirus vaccine approved in 2006. Today, Wistar is home to preeminent research programs studying skin cancer, lung cancer, and brain tumors. Wistar Institute Vaccine Center scientists are creating new vaccines against pandemic influenza, HIV, and other diseases threatening global health. The Institute works actively to transfer its inventions to the commercial sector to ensure that research advances move from the laboratory to the clinic as quickly as possible. The Wistar Institute: Today's Discoveries - Tomorrow's Cures. On the web at www.wistar.org.

The Wistar Institute

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.